New reports indicate that drug prices are slowing compared to other healthcare costs.
James C. Greenwood
Advertisement
Jim Greenwood is president and CEO of the Biotechnology Innovation Organization (BIO). He represented Pennsylvania’s 8th district in the US House of Representatives from 1993 to 2005.
Articles by James C. Greenwood
Policies for patient access to life-saving therapies must keep pace with biomedical innovation.
Protecting intellectual property rights is vital to biopharmaceutical innovation.
Sound policies are needed to govern the substitution of interchangeable biologics.
Ties between the biotechnology industry and university research are crucial.
BIO's president and CEO provides insight leading up to the 2011 convention.
This year's BIO International Convention will be occurring against a backdrop of profound change in our industry.
A key to bolstering FDA and its mission is securing balanced and consistent funding.
Advertisement
Latest Updated Articles
Prescribing Caution for BiosimilarsPublished: April 1st 2013 | Updated:
Technology Transfer: Protecting the True Public InterestPublished: September 1st 2012 | Updated:
Policy and InnovationPublished: June 1st 2011 | Updated:
Better Times Ahead for BiotechPublished: April 1st 2010 | Updated:
Final Word: New Organization Forms to Help FDA Fulfill its MissionPublished: December 1st 2006 | Updated:
Bureaucratic Roadblocks Threaten Biopharma GrowthPublished: June 1st 2014 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
